drugset / Trial / NCT00300404

Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression

NCT00300404

RandomizedParallel-groupDouble-blindTreatment

Summary

We investigate whether the add-on specific antitoxoplasmatic medication has positive effects in individuals with schizophrenia or major depression seropositive for Toxoplasma gondii (TG) infection. As TG modulates neurotransmitter metabolism affecting serotonin and dopamine we hypothesize that this chronic persistent infection might play a role for depressive and psychotic symptomatology. Therefore, on the basis of an ex juvantibus approach, specific anti TG medication might further improve psychiatric symptomatology in affected patients. This is investigated in a double-blind, placebo-controlled, randomized treatment trial.

Timeline

Start
2002-01
Primary completion
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject pyrimethamine Small molecule
Background Leucovorin Small molecule